In conclusion, current evidence suggests that the treatment with anti-TNF-α agents within the washout period of 12 weeks (3 months [18] or detectable serum concentrations [21]) prior to abdominal surgery is associated with important short-term general and surgical postoperative complications for patients with IBD, in particular with CD. Here, TNF is linked to inflammatory bowel disease.